An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer

A posteriori evidence suggests that radiotherapy to a targeted tumor can elicit an immune-mediated abscopal (ab-scopus, away from the target) effect in non-targeted tumors, when combined with an anti-cytotoxic T-lymphocyte antigen-4 monoclonal (CTLA-4) antibody. Concurrent radiotherapy and ipilimuma...

Full description

Saved in:
Bibliographic Details
Published in:Cancer immunology research 2013-12, Vol.1 (6), p.365-372
Main Authors: Golden, Encouse B, Demaria, Sandra, Schiff, Peter B, Chachoua, Abraham, Formenti, Silvia C
Format: Article
Language:English
Subjects:
Adenocarcinoma - drug therapy
Adenocarcinoma - immunology
Adenocarcinoma - radiotherapy
Adenocarcinoma - secondary
Antibodies, Monoclonal - therapeutic use
Antineoplastic Agents - therapeutic use
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - immunology
Carcinoma, Non-Small-Cell Lung - radiotherapy
Carcinoma, Non-Small-Cell Lung - secondary
Combined Modality Therapy
Humans
Ipilimumab
Lymphocytes, Tumor-Infiltrating - drug effects
Lymphocytes, Tumor-Infiltrating - radiation effects
Male
Middle Aged
Positron-Emission Tomography
Tomography, X-Ray Computed
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A posteriori evidence suggests that radiotherapy to a targeted tumor can elicit an immune-mediated abscopal (ab-scopus, away from the target) effect in non-targeted tumors, when combined with an anti-cytotoxic T-lymphocyte antigen-4 monoclonal (CTLA-4) antibody. Concurrent radiotherapy and ipilimumab (a human monoclonal anti-CTLA-4 antibody) induced immune-mediated abscopal effects in poorly immunogenic pre-clinical tumor models and metastatic melanoma patients. However, no such reports exist for patients with metastatic lung adenocarcinoma. We report the first abscopal response in a treatment-refractory lung cancer patient treated with radiotherapy and ipilimumab. A post-treatment increase in tumor-infiltrating cytotoxic lymphocytes, tumor regression, and normalization of tumor markers was observed. One year after treatment with concurrent radiotherapy and ipilimumab the patient is without evidence of disease.
ISSN:2326-6066
2326-6074
DOI:10.1158/2326-6066.CIR-13-0115